NSU-MD Faculty Articles
Title
Combination therapy for renal cell cancer: what are possible options?
ISBN or ISSN
0030-2414
Publication Title
Oncology
Volume
81
Issue
3-4
Publication Date / Copyright Date
1-1-2011
First Page
220
Last Page
229
Publisher
S. Karger AG
DOI Number
10.1159/000333470
Abstract
Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC). Two classes of antiangiogenic drugs, the anti-vascular endothelial growth factor antibody bevacizumab and the tyrosine kinase inhibitors sorafenib, sunitinib and pazopanib, have shown efficacy in patients with RCC and are approved by the US Food and Drug Administration for treatment of this cancer. In practice, the clinical benefit of antiangiogenic drugs in RCC has been heterogeneous, and in patients who do respond, benefits are modest and/or short-lived. To improve efficacy, combination targeted therapy has been attempted, but with either very limited additional efficacy or nontolerable toxicities. Recent advances in the molecular understanding of tumor angiogenesis and mechanism of resistance, along with the rapid development of targeted drug discovery, have made it possible to further explore novel combination therapy for RCC.
Disciplines
Medicine and Health Sciences
Keywords
Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Neovascularization, Pathologic
NSUWorks Citation
Santos, Napoleon; Wenger, Justin B; Havre, Pamela; Liu, Yanxia; Dagan, Roi; Imanirad, Iman; Ivey, Alison M; Zlotecki, Robert A; Algood, Chester B; Gilbert, Scott M; Allegra, Carmen J; Okunieff, Paul; Vieweg, Johannes; Dang, Nam H; Luesch, Hendrik; and Dang, Long H, "Combination therapy for renal cell cancer: what are possible options?" (2011). NSU-MD Faculty Articles. 61.
https://nsuworks.nova.edu/hpd_md_facarticles/61
